Favorable Outcome in 20-Year Follow-Up of Children with Very-Low-Risk ALL and Minimal Standard Therapy, with Special Reference to TEL-AML1 Fusion

Pediatric Blood and Cancer

Volumn 42, Issue 1, 2004, Pages 30-35

  Kanerva, Jukka ^a   Saarinen Pihkala, Ulla M ^a   Niini, Tarja ^b   Riikonen, Pekka ^c   Möttönen, Merja ^d   Mäkipernaa, Anne ^e   Salmi, Toivo T ^f   Vettenranta, Kim ^a   Knuutila, Sakari ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Childhood; Leukemia; Long term follow up; TEL AML1 fusion

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER CLASSIFICATION; CANCER SURVIVAL; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE; GENE FUSION; HUMAN; INFANT; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SKULL IRRADIATION; STATISTICAL ANALYSIS; TEL AML1 GENE;

EID: 0842313000     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.10417     Document Type: Article

References (18)

1. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997;90:4243-4251.
2. Margolin JF, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo P, Poplack D, Pizzo P, Poplack DG, editors. Principles and practice in pediatric oncology. Philadelphia and New York: J. B. Lippincott Company; 1997. pp 409-462.
3. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
4. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997;90:571-577.
5. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996;88:4252-4258.
6. Rubnitz JE, Behm FG, Wichlan D, et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999;13:19-21.
7. Seeger K, Adams HP, Buchwald D, et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 1998;91:1716-1722.
8. Loh ML, Silverman LB, Young ML, Neuberg D, et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998;92:4792-4797.
9. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 2000;14:2267-2275.
10. Pihkala J, Saarinen UM, Lundstrom U, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996;32A:97-103.
11. Saarinen UM. Severe infections in childhood leukemia. A follow-up study of 100 consecutive ALL patients. Acta Paediatr 1984;73:515-522.
12. Gustafsson G, Kreuger A, Clausen N, et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: The Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO) [in process citation]. Acta Paediatr 1998;87:1151-1161.
13. Kanerva J, Tiirikainen M, Makipernaa A, et al. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL. Pediatr Hematol Oncol 1998;15:11-21.
14. Hirt A, Leibundgut K, Luthy AR, et al. Cell birth and death in childhood acute lymphoblastic leukaemia: How fast does the neoplastic cell clone expand? Br J Haematol 1997;98:999-1001.
15. Martinez-Climent JA. Molecular cytogenetics of childhood hematological malignancies. Leukemia 1997;11:1999-2021.
16. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia-the importance of early marrow response: Report from the Childrens Cancer Group. J Clin Oncol 1996;14:389-398.
17. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9:1985-1989.
18. 2). N Engl J Med 1983;308:559-565.